Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo

Nucleic Acids Research

Volumn 46, Issue 5, 2018, Pages 2185-2196

  Hassler, Matthew R ^a   Turanov, Anton A ^a   Alterman, Julia F ^a   Haraszti, Reka A ^a   Coles, Andrew H ^a   Osborn, Maire F ^a   Echeverria, Dimas ^a   Nikan, Mehran ^a   Salomon, William E ^a   Roux, Loïc ^a   Godinho, Bruno M D C ^a   Davis, Sarah M ^a   Morrissey, David V ^b   Zamore, Phillip D ^a   Ananth Karumanchi, S ^c   Moore, Melissa J ^a   Aronin, Neil ^a   Khvorova, Anastasia ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Novartis Institutes of Biomedical Research   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CHOLESTEROL; DOCOSAHEXAENOIC ACID; N ACETYLGALACTOSAMINE; PEPTIDE; PEPTIDE NUCLEIC ACID; SMALL INTERFERING RNA; LIPID;

ANIMAL CELL; ARTICLE; CHEMICAL MODIFICATION; DRUG DELIVERY SYSTEM; EMBRYO; GENE SILENCING; HELA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERMETHOD COMPARISON; MEF CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; RNA SEQUENCE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; COMPARATIVE STUDY; FEMALE; GENE VECTOR; GENETICS; PROCEDURES; RNA PROCESSING; TISSUE DISTRIBUTION;

ANIMALS; APTAMERS, NUCLEOTIDE; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC VECTORS; HELA CELLS; HUMANS; LIPIDS; MICE, INBRED C57BL; PEPTIDES; RNA INTERFERENCE; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

EID: 85047830699     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gky037     Document Type: Article

References (48)

1. Watts, J.K. and Corey, D.R. (2012) Silencing disease genes in the laboratory and the clinic. J. Pathol., 226, 365-379.
2. Deleavey, G.F., Watts, J.K., Alain, T., Robert, F., Kalota, A., Aishwarya, V., Pelletier, J., Gewirtz, A.M., Sonenberg, N. and Damha, M.J. (2010) Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Res., 38, 4547-4557.
3. Allerson, C.R., Sioufi, N., Jarres, R., Prakash, T.P., Naik, N., Berdeja, A., Wanders, L., Griffey, R.H., Swayze, E.E. and Bhat, B. (2005) Fully 2-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem., 48, 901-904.
4. Choung, S., Kim, Y.J., Kim, S., Park, H.O. and Choi, Y.C. (2006) Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun., 342, 919-927.
5. Czauderna, F., Fechtner, M., Dames, S., Aygun, H., Klippel, A., Pronk, G.J., Giese, K. and Kaufmann, J. (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res., 31, 2705-2716.
6. Judge, A.D., Bola, G., Lee, A.C. and MacLachlan, I. (2006) Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther., 13, 494-505.
7. Chen, Q., Butler, D., Querbes, W., Pandey, R.K., Ge, P., Maier, M.A., Zhang, L., Rajeev, K.G., Nechev, L., Kotelianski, V. et al. (2010) Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J. Controlled Release, 144, 227-232.
8. Wolfrum, C., Shi, S., Jayaprakash, K.N., Jayaraman, M., Wang, G., Pandey, R.K., Rajeev, K.G., Nakayama, T., Charrise, K., Ndungo, E.M. et al. (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotech., 25, 1149-1157.
9. Dohmen, C., Frohlich, T., Lachelt, U., Rohl, I., Vornlocher, H.-P., Hadwiger, P. and Wagner, E. (2012) Defined folate-PEG-siRNA conjugates for receptor-specific gene silencing. Mol. Ther. Nucleic Acids, 1, e7.
10. Nishina, K., Unno, T., Uno, Y., Kubodera, T., Kanouchi, T., Mizusawa, H. and Yokota, T. (2008) Efficient in vivo delivery of siRNA to the liver by conjugation of [alpha]-tocopherol. Mol. Ther., 16, 734-740.
11. McNamara, J.O., Andrechek, E.R., Wang, Y., Viles, K.D., Rempel, R.E., Gilboa, E., Sullenger, B.A. and Giangrande, P.H. (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotech, 24, 1005-1015.
12. Cuellar, T.L., Barnes, D., Nelson, C., Tanguay, J., Yu, S.-F., Wen, X., Scales, S.J., Gesch, J., Davis, D., van Brabant Smith, A. et al. (2015) Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res., 43, 1189-1203.
13. Nair, J.K., Willoughby, J.L., Chan, A., Charisse, K., Alam, M.R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel'in, A.V., Milstein, S. et al. (2014) Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc., 136, 16958-16961.
14. Nair, J.K., Attarwala, H., Sehgal, A., Wang, Q., Aluri, K., Zhang, X., Gao, M., Liu, J., Indrakanti, R., Schofield, S. et al. (2017) Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res., 45, 10969-10977.
15. Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H.B., Cleveland, D.W., Swayze, E.E., Lima, W.F., Crooke, S.T., Prakash, T.P. and Corey, D.R. (2012) Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell, 150, 895-908.
16. Lima,Walt F., Prakash,Thazha P., Murray,Heather M., Kinberger,Garth A., Li,W., Chappell,Alfred E., Li,Cheryl S., Murray,Susan F., Gaus,H., Seth,Punit P. et al. (2012) Single-stranded siRNAs activate RNAi in animals. Cell, 150, 883-894.
17. Prakash, T.P., Kinberger, G.A., Murray, H.M., Chappell,A., Riney,S., Graham,M.J., Lima,W.F., Swayze,E.E. and Seth,P.P. (2016) Synergistic effect of phosphorothioate, 5-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA. Bioorg. Med. Chem. Lett., 26, 2817-2820.
18. Prakash, T.P., Lima, W.F., Murray, H.M., Li, W., Kinberger, G.A., Chappell, A.E., Gaus, H., Seth, P.P., Bhat, B., Crooke, S.T. et al. (2017) Identification of metabolically stable 5-phosphate analogs that support single-stranded siRNA activity. Nucleic Acids Res., 45, 6994.
19. Haraszti, R.A., Roux, L., Coles, A.H., Turanov, A.A., Alterman , J.F., Echeverria, D., Godinho, B., Aronin, N. and Khvorova, A. (2017) 5-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids Res., 45, 7581-7592.
20. Osborn, M.F., Alterman, J.F., Nikan, M., Cao, H., Didiot, M.C., Hassler, M.R., Coles, A.H. and Khvorova, A. (2015) Guanabenz (Wytensin) selectively enhances uptake and efficacy of hydrophobically modified siRNAs. Nucleic Acids Res., 43, 8664-8672.
21. Salomon, W.E., Jolly, S.M., Moore, M.J., Zamore, P.D. and Serebrov, V. (2015) Single-molecule imaging reveals that argonaute reshapes the binding properties of its nucleic acid guides. Cell, 162, 84-95.
22. Alterman J.F., Coles, A.H., Hall, L.M., Aronin, N., Khvorova, A. and Didiot, M.C. (2017) A High-throughput Assay for mRNA Silencing in Primary Cortical Neurons in vitro with Oligonucleotide Therapeutics. Bio Protoc, 7, e2501.
23. Coles, A.H., Osborn, M.F., Alterman, J.F., Turanov, A.A., Godinho, B.M., Kennington, L., Chase, K., Aronin, N. and Khvorova, A. (2016) A high-throughput method for direct detection of therapeutic oligonucleotide-induced gene silencing in vivo. Nucleic Acid Ther., 26, 86-92.
24. Godinho, B., Gilbert, J.W., Haraszti, R.A., Coles, A.H., Biscans, A., Roux, L., Nikan, M., Echeverria, D., Hassler, M. and Khvorova, A. (2017) Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to peptide nucleic acid hybridization assay. Nucleic Acid Ther., 27, 323-334.
25. Roehl, I., Schuster, M. and Seiffert, S. (2008) Oligonucleotide Detection Method. US20110201006.
26. Matranga, C., Tomari, Y., Shin, C., Bartel, D.P. and Zamore, P.D. (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell, 123, 607-620.
27. Eckstein, F. (2014) Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther., 24, 374-387.
28. Byrne, M., Tzekov, R., Wang, Y., Rodgers, A., Cardia, J., Ford, G., Holton, K., Pandarinathan, L., Lapierre, J., Stanney, W. et al. (2013) Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. J. Ocular Pharmacol. Ther., 29, 855-864.
29. Nikan, M., Osborn, M.F., Coles, A.H., Godinho, B.M.D.C., Hall, L.M., Haraszti, R.A., Hassler, M.R., Echeverria, D., Aronin, N. and Khvorova, A. (2016) Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain. Mol. Ther. Nucleic Acids, 5, e344.
30. Alterman, J.F., Hall, L.M., Coles, A.H., Hassler, M.R., Didiot, M.C., Chase, K., Abraham, J., Sottosanti, E., Johnson, E., Sapp, E. et al. (2015) Hydrophobically modified siRNAs silence Huntingtin mRNA in primary neurons and mouse brain. Mol. Ther. Nucleic Acids, 4, e266.
31. Khvorova, A. and Watts, J.K. (2017) The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol., 35, 238-248.
32. Ly, S., Navaroli, D.M., Didiot, M.C., Cardia, J., Pandarinathan, L., Alterman, J.F., Fogarty, K., Standley, C., Lifshitz, L.M., Bellve, K.D. et al. (2017) Visualization of self-delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Res., 45, 15-25.
33. Nikan, M., Osborn, M.F., Coles, A.H., Biscans, A., Godinho, B., Haraszti, R.A., Sapp, E., Echeverria, D., DiFiglia, M., Aronin, N. et al. (2017) Synthesis and evaluation of parenchymal retention and efficacy of a metabolically stable O-phosphocholine-N-docosahexaenoyl-l-serine siRNA conjugate in mouse brain. Bioconjug. Chem., 28, 1758-1766.
34. Jackson, A.L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo,J., Johnson, J.M., Lim, L., Karpilow, J., Nichols, K. et al. (2006) Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA (New York, N.Y.), 12, 1197-1205.
35. Dahlman, J.E., Barnes, C., Khan, O.F., Thiriot, A., Jhunjunwala, S., Shaw, T.E., Xing, Y., Sager, H.B., Sahay, G., Speciner, L. et al. (2014) In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Nano, 9, 648-655.
36. Dass, C.R. and Burton, M.A. (2002) Modified microplex vector enhances transfection of cells in culture while maintaining tumour-selective gene delivery in-vivo. J. Pharm. Pharmacol., 55, 19-25.
37. Karra, D. and Dahm, R. (2010) Transfection techniques for neuronal cells. J. Neurosci., 30, 6171-6177.
38. Wee, L.M., Flores-Jasso, C.F., Salomon, W.E. and Zamore, P.D. (2012) Argonaute divides its RNA guide into domains with distinct functions and RNA-binding properties. Cell, 151, 1055-1067.
39. Nair, J.K., Willoughby, J.L.S., Chan, A., Charisse, K., Alam, M.R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel'in, A.V., Milstein, S. et al. (2014) Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc., 136, 16958-16961.
40. Parmar, R., Willoughby, J.L., Liu, J., Foster, D.J., Brigham, B., Theile, C.S., Charisse, K., Akinc, A., Guidry, E., Pei, Y. et al. (2016) 5-(E)-Vinylphosphonate: a stable phosphate mimic can improve the RNAi activity of siRNA-GalNAc conjugates. Chembiochem, 17, 985-989.
41. Rozema, D.B., Lewis, D.L., Wakefield, D.H., Wong, S.C., Klein, J.J., Roesch, P.L., Bertin, S.L., Reppen, T.W., Chu, Q., Blokhin, A.V. et al. (2007) Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. U.S.A., 104, 12982-12987.
42. Watts, J.K., Deleavey, G.F. and Damha, M.J. (2008) Chemically modified siRNA: tools and applications. Drug Discov. Today, 13, 842-855.
43. Deleavey, G.F., Frank, F., Hassler, M., Wisnovsky, S., Nagar, B. and Damha, M.J. (2013) The 5 binding MID domain of human Argonaute2 tolerates chemically modified nucleotide analogues. Nucleic Acid Ther., 23, 81-87.
44. Manoharan, M., Akinc, A., Pandey, R.K., Qin, J., Hadwiger, P., John, M., Mills, K., Charisse, K., Maier, M.A., Nechev, L. et al. (2011) Unique gene-silencing and structural properties of 2-fluoro-modified siRNAs. Angew. Chem. Int. Ed. Engl., 50, 2284-2288.
45. Schirle, N.T., Sheu-Gruttadauria, J. and MacRae, I.J. (2014) Structural basis for microRNA targeting. Science (New York, N.Y.), 346, 608-613.
46. Schirle, N.T., Kinberger, G.A., Murray, H.F., Lima, W.F., Prakash, T.P. and MacRae, I.J. (2016) Structural analysis of human argonaute-2 bound to a modified siRNA guide. J. Am. Chem. Soc., 138, 8694-8697.
47. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J. et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432, 173-178.
48. Khan, T., Weber, H., DiMuzio, J., Matter, A., Dogdas, B., Shah, T., Thankappan, A., Disa, J., Jadhav, V., Lubbers, L. et al. (2016) Silencing myostatin using cholesterol-conjugated siRNAs induces muscle growth. Mol. Ther. Nucleic Acids, 5, e342.